Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$132000.0.

  • Keros Therapeutics' Cash from Investing Activities rose 6580.31% to -$132000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 2185.07%. This contributed to the annual value of -$1.9 million for FY2024, which is 2163.15% up from last year.
  • Per Keros Therapeutics' latest filing, its Cash from Investing Activities stood at -$132000.0 for Q3 2025, which was up 6580.31% from -$720000.0 recorded in Q2 2025.
  • Keros Therapeutics' Cash from Investing Activities' 5-year high stood at -$132000.0 during Q3 2025, with a 5-year trough of -$1.1 million in Q1 2023.
  • In the last 5 years, Keros Therapeutics' Cash from Investing Activities had a median value of -$351000.0 in 2022 and averaged -$425105.3.
  • As far as peak fluctuations go, Keros Therapeutics' Cash from Investing Activities tumbled by 172142.86% in 2021, and later skyrocketed by 6580.31% in 2025.
  • Quarter analysis of 5 years shows Keros Therapeutics' Cash from Investing Activities stood at -$159000.0 in 2021, then crashed by 120.75% to -$351000.0 in 2022, then tumbled by 54.13% to -$541000.0 in 2023, then surged by 46.58% to -$289000.0 in 2024, then soared by 54.33% to -$132000.0 in 2025.
  • Its Cash from Investing Activities was -$132000.0 in Q3 2025, compared to -$720000.0 in Q2 2025 and -$565000.0 in Q1 2025.